Growblox Sciences, Inc. (GBLX), a biopharmaceutical company with state-of-the-art technologies in plant biology and cultivation designed to produce consistent medicinal cannabis, announced today the receipt of production-model GrowBLOX(TM) units for both GB Sciences Nevada (GBSN) and GB Sciences Puerto Rico (GBS PR).
“This is a major milestone for our company as it signals the transition from development to commercialization of our unique cannabis cultivation technology. We didn’t set out to reinvent cannabis cultivation, but we believe that ‘if you can’t measure it, you can’t control it’. Therefore, we had to invent a series of proprietary chambers to control and monitor all stages of plant growth from tissue culture in the TissueBLOX, to maturation in the GrowBLOX, through curing in the CureBLOX,” stated Craig Ellins, CEO of Growblox Sciences, Inc. “All of the hardware and software improvements that we discovered during the development phases have been incorporated into these productions models, and we are eager to begin the validation process driven largely from our Puerto Rico location under the direction of Jorge Velez, Project Manager at GBS PR. Jorge is a 25-year veteran of the pharmaceutical industry and is ideally qualified to validate our technology according to rigorous pharmaceutical standards.”
Validation of the GrowBLOX(TM) technology suite will include the development of a remote monitoring and diagnostic services program, as well as tissue-culture propagation and plant-genotype, cryogenic banking services. In addition, GBS PR will be responsible for implementing the GBLX quality management system to assure that all aspects of the cultivation of medical cannabis in the GrowBLOX(TM) technology suite conform to Current Good Manufacturing Practices (or cGMP). As regulated by the FDA, cGMP processes are followed by pharmaceutical and biotechnology firms to ensure that their certified products meet specific requirements for identity, strength, quality, and purity.
Dr. Andrea Small-Howard, Chief Science Officer of Growblox Sciences noted, “Creating cGMP-certified cannabis materials is the key to bringing cannabis and cannabis-based therapies out of state-regulated dispensaries and into larger federally-regulated markets including those for nutraceutical, cosmeceutical and pharmaceutical products. These cGMP certified materials represent the best starting point for scientifically validating the effectiveness of cannabinoid therapies for patients within regulated markets. Current studies of medical cannabis often lack properly controlled and dosed starting materials, but our trials will use standardized starting materials in order to evaluate the effectiveness to FDA standards. Our diligence through the research and development phase of our GrowBLOX technology suite was geared toward meeting this pharmaceutical standard.”
The GrowBLOX chambers had successfully completed several phases of testing and re-design in order to maximize the efficiency of this proprietary cultivation system. In May of 2014, GBLX had reported that a development stage version of the GrowBLOX(TM) had been produced for evaluation in China by Wayne Love, Lead Product Engineer at GBLX. The first GrowBLOX(TM) units arrived in Las Vegas, NV in August of 2014 for evaluation by Dr. Ulrich Reimann-Philipp, Biologist and Cultivation Manager at GBLX. Dr. Reimann-Philip’s goal was to optimize the growth conditions within the GrowBLOX and implement hardware and software updates.
About Growblox Sciences, Inc.
Growblox Sciences, Inc. (GBLX) is a biopharmaceutical research and development company focused on creating safe, standardized pharmaceutical-grade cannabis-based therapies that target a variety of medical conditions. The Company is leading pioneering technology and industry processes, with a “big” data-driven clinical research and development loop ability to bring relief to patients in communities across the country. Through our GBS PR subsidiary, we are developing and globally distributing our GrowBLOXTM suite of cultivation and growing chambers. To learn more about Growblox Sciences, Inc., go to www.gbsciences.com.
Forward-Looking Statements: This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as presently constituted.
GrowBLOX is a registered trademark of Growblox Sciences, Inc.
Growblox Sciences, Inc., 6450 Cameron Street, Suite 110A, Las Vegas, NV 89118 866.721.0297 Craig Ellins, CEO; Andrea Small Howard, Chief Science Officer. firstname.lastname@example.org email@example.com https://gbsciences.com
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | firstname.lastname@example.org